The company opened its new global headquarters in Japan.
Takeda Pharmaceutical announced the opening of its new headquarters in Nihonbashi, Tokyo on July 2, 2018. The building was completed in March 2018.
The company announced that it agreed to sell its previous Tokyo headquarters as well as its Shin-Edobashi building to Takashimaya Company in December 2017 for 49.5 yen (approximately US$447 million).
Source: Takeda Pharmaceutical
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 5th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.